MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Arbutus Biopharma Corp

Gesloten

4.18 -3.02

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.16

Max

4.28

Belangrijke statistieken

By Trading Economics

Inkomsten

27M

2.5M

Verkoop

9M

11M

Winstmarge

23.494

Werknemers

44

EBITDA

27M

2.6M

Marktinformatie

By TradingEconomics

Marktkapitalisatie

215M

855M

Vorige openingsprijs

7.2

Vorige sluitingsprijs

4.18

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Arbutus Biopharma Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 okt 2025, 16:58 UTC

Winsten

BMW Trims 2025 View, Citing Weaker Performance in China

7 okt 2025, 23:43 UTC

Marktinformatie

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 okt 2025, 23:36 UTC

Marktinformatie

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 okt 2025, 23:19 UTC

Marktinformatie

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 okt 2025, 22:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 22:50 UTC

Marktinformatie

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 okt 2025, 22:40 UTC

Marktinformatie

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 okt 2025, 21:56 UTC

Marktinformatie

Global Equities Roundup: Market Talk

7 okt 2025, 21:56 UTC

Marktinformatie

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 okt 2025, 20:44 UTC

Populaire aandelen

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 okt 2025, 19:42 UTC

Marktinformatie

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 okt 2025, 19:23 UTC

Acquisities, Fusies, Overnames

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 okt 2025, 19:07 UTC

Marktinformatie

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 okt 2025, 19:02 UTC

Marktinformatie

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

7 okt 2025, 16:20 UTC

Marktinformatie

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 okt 2025, 16:15 UTC

Marktinformatie

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 okt 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

7 okt 2025, 15:37 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 15:37 UTC

Marktinformatie

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 okt 2025, 15:33 UTC

Marktinformatie

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 okt 2025, 15:25 UTC

Marktinformatie

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 okt 2025, 15:15 UTC

Marktinformatie

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 okt 2025, 15:04 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

7 okt 2025, 15:04 UTC

Marktinformatie

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 okt 2025, 14:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

7 okt 2025, 14:56 UTC

Marktinformatie

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 okt 2025, 14:52 UTC

Winsten

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Arbutus Biopharma Corp Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Technische score

By Trading Central

3.255 / 3.365Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
help-icon Live chat